**Chapter 9**

*Cells of the Immune System*

2018;**5**(1):1536097

2013;**368**(26):2455-2466

2014;**371**:1189-1197

2019;**8**:212580

[84] Henriksen DP, Bodtger U, Sidenius K, Maltbaek N, Pedersen L, Madsen H, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma—A systematic review and meta-analysis. European Clinical Respiratory Journal.

[91] Matera MG, Calzetta L, Rinaldi B,

[92] Coumou H, Bel EH. Improving the diagnosis of eosinophilic asthma. Expert Review of Respiratory Medicine.

Cazzola M. Pharmacokinetic/ pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology.

2017;**13**(9):1007-1013

2016;**10**(10):1093-1103

[93] Agache I, Jessica Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica W, et al. Efficacy and safety of treatment with biologicals

(benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. Allergy. 8 February 2020. DOI:

Journal of Internal Medicine.

2016;**279**(2):192-204

[94] Chung KF. Asthma phenotyping: A necessity for improved therapeutic precision and new targeted therapies.

10.1111/all.14221

[85] Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. The New England Journal of Medicine.

[86] Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet. 2012;**380**(9842):651-659

[87] Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. The New England Journal of Medicine.

[88] Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, et al. Benralizumab: From the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. BioMed Research International. 2018;**2018**:4839230

[89] Menzella F, Biava M, Bagnasco D, Galeone C, Simonazzi A, Ruggiero P, et al. Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors? Drugs in Context.

[90] Sridhar S, Liu H, Pham TH, Damera G, Newbold P. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respiratory Research. 2019;**20**(1):14

**152**
